Biomarkers for the prediction of blood pressure response to renal denervation: A long way to go

Hypertension

Volumn 63, Issue 5, 2014, Pages 907-908

  Schlaich, Markus ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN TYROSINE KINASE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; NOTE; PATIENT SELECTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; RESISTANT HYPERTENSION; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MALE; SYMPATHECTOMY; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84902260499     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02752     Document Type: Note

References (10)

1. Krum H, Schlaich M, Whitbourn R., Sobotka PA, Sadowski J, Bartus K, Kapelak B., Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281.
2. Esler MD, Krum H, Sobotka P.A., Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010; 376: 1903-1909.
3. Krum H, Schlaich MP, Bohm M, Mahfoud F., Rocha-Singh K, Katholi R, Esler MD Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014. In press.
4. Persu A, Jin Y, Azizi M., et al Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014. In press.
5. Esler MD, Krum H, Schlaich M., Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012; 126: 2976-2982.
6. Mahfoud F, Ukena C, Schmieder R.E., et al Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013; 128: 132-140.
7. Zuern CS, Eick C, Rizas K.D., Bauer S., Langer H, Gawaz M, Bauer A. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013; 62: 2124-2130.
8. Dörr O., Liebetrau C, Möllmann H, Gaede L., Troidl C, Rixe J, Hamm C., Nef H. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014; 63: 984-990.
9. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001; 87: 805-807, A9. (Pubitemid 32209107)
10. Hering D, Lambert EA, Marusic P, Walton A.S., Krum H., Lambert GW, Esler MD, Schlaich MP Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013; 61: 457-464.